Today: 11 June 2026
Vanguard’s VTI pulls in $852 million even as shares fall for the week
18 May 2026
2 mins read

Vanguard’s VTI pulls in $852 million even as shares fall for the week

New York, May 18, 2026, 10:08 EDT

Vanguard Total Stock Market ETF (VTI) pulled in $852.57 million of net inflows over five days, TipRanks’ automated newsdesk reported. The ETF slipped 0.24% for the week. Net inflows track new money in minus any withdrawn.

The timing is key as this trade is central to the U.S. market right now. Investors keep chasing exposure to artificial-intelligence leaders within big benchmarks, but higher bond yields and inflation from energy prices are starting to test the rally’s strength.

S&P 500, Nasdaq started up Monday as chip stocks bounced back and bond selling eased, Reuters said. Dow was lower at the open. S&P 500 up 0.09%, Nasdaq up 0.25%.

VTI, the exchange-traded fund, changed hands at $363.71, up $0.97 from the last close. Other broad-market funds also moved higher. iShares Core S&P Total U.S. Stock Market ETF hit $161.53. Schwab U.S. Broad Market ETF traded at $28.46. Invesco QQQ Trust, which tracks tech, was at $709.54.

VTI holds a wide mix of stocks, but it still swings with tech. Morningstar says the fund tracks the CRSP U.S. Total Market Index, which picks investable U.S. names and weighs them by market cap, so the largest companies matter most. On March 31, Nvidia, Apple and Microsoft topped its list of holdings.

TipRanks tied interest in VTI to big positions in Nvidia, Apple and Microsoft. Nvidia goes into its fiscal first-quarter report this week, and the market is watching AI chip demand. That’s part of what’s bringing in the flows, TipRanks said.

Global flows are still running hot. LSEG Lipper figures tracked by Reuters showed global equity funds bringing in $39.15 billion in the week to May 13, the eighth week in a row of inflows. U.S. equity funds pulled in $22.37 billion, and technology funds set a new record with $10.65 billion.

But risks are getting more attention. Reuters said investors warn that pricey U.S. stock levels may not reflect the threat from rising inflation, high oil prices, and a jump in Treasury yields. Peter Tuz at Chase Investment Counsel said there is “a real fear” inflation is sticking. Jack Ablin from Cresset Capital pointed to worries of a “brand new inflation regime” if the Strait of Hormuz stays closed for months. Reuters

VTI is facing pressure from rising yields, which can draw money away from stocks and into bonds. Higher yields tend to weigh on equity valuations, a problem when much of the market’s recent move has come from a handful of high-priced megacaps.

Bulls are sticking with earnings. Jeremiah Buckley, portfolio manager at Janus Henderson, told Reuters that investors are seeing effects from the AI spending boom and productivity gains. He said that could keep going through 2027.

VTI investors are still putting money into the fund, but the U.S. market it tracks is dominated by a handful of big tech stocks. The fund offers wide market exposure, though most gains are coming from those large tech names. The recent inflows don’t mean the risks have disappeared.

Stock Market Today

  • Johnson Controls International (JCI) Valuation Review Amid Recent Share Decline
    June 11, 2026, 10:52 AM EDT. Johnson Controls International (NYSE:JCI) shares fell 5.7% recently, despite solid annual revenue of US$24.4 billion and net income of US$2 billion. The stock trades slightly above its fair value estimate of US$138.11, which factors in a 9.38% discount rate and modest revenue growth forecast of 5.56%. Analyst models reflect steadier revenue expansion and improved profit margins, yet caution remains due to potential operational disruptions from a new segment structure and execution risks related to cost-saving initiatives. Investors are urged to evaluate both risks and rewards amid the short-term price weakness and maintain a close watch on ongoing financial performance and strategic execution.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Hims & Hers Sinks Pre-Market After Debt Deal Fuels Dilution Talk
Previous Story

Hims & Hers Sinks Pre-Market After Debt Deal Fuels Dilution Talk

TSMC’s $1.5 Trillion AI Chip Move Pressures Samsung, Intel
Next Story

TSMC’s $1.5 Trillion AI Chip Move Pressures Samsung, Intel

Go toTop